# Infusional C-myb ASODN in Advanced Hematologic Malignancies

> **NCT00780052** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 13 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** c-myb AS ODN

## Key facts

- **NCT ID:** NCT00780052
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780052, "Infusional C-myb ASODN in Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00780052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*